Latest News & Features
Big Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis. 2 January 2024
Biotechnology
Mark Hatch-Miller, who led the trial team at Susman for Globus, tells Sarah Speight how this spinal implant patent dispute, brought by a Johns Hopkins neurosurgeon, was a “heavy lift”. 21 December 2023
Asia
A Korean district court has applied a landmark ruling in a complicated vaccine dispute involving Pfizer, explain Young Kim, Yu-Seog WON, In Hwan Kim, and Amy Oh of Kim & Chang. 12 December 2023
Biotechnology
Patent applications need to offer the full picture when it comes to scientific research, finds Marisa Woutersen at LSPN Europe. 30 November 2023
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger. 28 November 2023
Americas
An ambiguous decision by the Supreme Court has paved the way for frivolous petitions for compensation and clarity is needed, say Daniel Sanchez and Karla Olvera of Olivares. 28 November 2023
Biotechnology
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF. 21 November 2023
Americas
Securing IP protection in Brazil for the ‘bio-ink’ used to print new human tissue has challenges but composition is key, say Priscila Kashiwabara and Breno Souza of Kasznar Leonardos. 16 November 2023
Biotechnology
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction delays a generic's launch but the patent is invalidated or there is a finding of non-infringement. 26 October 2023
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills. 26 October 2023